View Older Stories View More Recent Stories

May 7, 2020 07:00AM Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 6, 2020 07:00AM Ionis reports first quarter 2020 financial results and recent business achievements
May 5, 2020 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2020
May 1, 2020 07:05AM Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
Apr 22, 2020 07:05AM Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Apr 20, 2020 07:08AM Ionis Pharmaceuticals (IONS), Roche Report Complete Patient Enrollment of Global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 20, 2020 07:05AM Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 8, 2020 07:05AM Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
Apr 7, 2020 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Apr 2, 2020 07:35AM Biogen (BIIB) Reports First Patient Treated with Higher Dose of SPINRAZA (nusinersen) in Phase 2/3 DEVOTE Study
Apr 2, 2020 07:30AM Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Mar 24, 2020 07:04AM Akcea Therapeutics (AKCA) Announces Dr. Damien McDevitt as CEO
Mar 24, 2020 07:03AM Akcea Therapeutics (AKCA) Announces Appointment of Dr. Damien McDevitt as CEO
Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Mar 11, 2020 07:00AM Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 28, 2020 07:00AM Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Feb 27, 2020 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Ionis provides fourth quarter and full year 2019 financial results
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 25, 2020 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
Feb 19, 2020 07:05AM Ionis Pharmaceuticals to hold 2019 financial results webcast
Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
Feb 18, 2020 07:00AM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Feb 13, 2020 07:00AM Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Feb 11, 2020 07:16AM Ionis Pharmaceuticals (IONS) treatment for Alexander disease granted orphan drug status from EMA
Feb 11, 2020 07:05AM Ionis treatment for Alexander disease granted orphan drug status from EMA
Jan 28, 2020 04:08PM Akcea Therapeutics (AKCA) and Ionis (IONS) report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 28, 2020 04:05PM Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 22, 2020 07:08AM Ionis Pharmaceuticals (IONS), Akcea Therapeutics (AKCA) Announce Positive Topline Phase 2 Results of AKCEA-APOCIII-L Rx
Jan 22, 2020 07:05AM Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020 07:04AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Report Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 10, 2020 07:00AM Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 9, 2020 07:05AM Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 7, 2020 07:05AM Ionis' neurological franchise marks year of achievement
Jan 7, 2020 07:05AM /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
Jan 6, 2020 07:05AM Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Jan 2, 2020 08:01AM Akcea Therapeutics (AKCA) Reports Publication of Results from Phase 2 Study of AKCEA-APO(a)-LRx
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Jan 2, 2020 08:00AM New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Dec 19, 2019 07:08AM Ionis Pharmaceuticals (IONS) licenses investigational Alzheimer's therapy to Biogen (BIIB)
View More Recent Stories View Older Stories